Charles Anthony Laranjeira - Jun 6, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jun 6, 2022
Transactions value $
-$467,961
Form type
4
Date filed
6/8/2022, 07:39 PM
Previous filing
Nov 24, 2021
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale -$173K -2.81K -8.37% $61.37 30.8K Jun 6, 2022 Direct F1
transaction PCRX Common Stock Sale -$149K -2.52K -8.19% $59.08 28.3K Jun 8, 2022 Direct F2, F3
transaction PCRX Common Stock Sale -$98.4K -1.63K -5.78% $60.23 26.6K Jun 8, 2022 Direct F2, F4
transaction PCRX Common Stock Sale -$31.5K -516 -1.94% $60.99 26.1K Jun 8, 2022 Direct F2, F5
transaction PCRX Common Stock Sale -$16.5K -267 -1.02% $61.98 25.9K Jun 8, 2022 Direct F2, F6
transaction PCRX Common Stock Award $0 +9.9K +38.29% $0.00 35.8K Jun 8, 2022 Direct F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +24.8K $0.00 24.8K Jun 8, 2022 Common Stock 24.8K $59.39 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.65, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 6.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.80 to $60.76, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.41, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.92 to $62.02, inclusive.
F7 Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F8 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.